Skip to main content

Table 1 Mole percentage of fatty acids in H9C2 cell (total cell lysate or mitochondria) after 24 h treatment with 100 μM EPA or 50 μM DHA

From: N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2

Fatty acid Total Mitochondria
(Mol %) Control EPA DHA Control EPA DHA
C12:0 1.16 ± 0.43 1.55 ± 0.32 1.58 ± 0.24 1.25 ± 0.32 1.19 ± 0.25 1.76 ± 0.33
C14:0 0.60 ± 0.06 0.86 ± 0.06 1.05 ± 0.07 0.98 ± 0.02 0.83 ± 0.04 0.72 ± 0.05
C15:0 0.21 ± 0.06 0.22 ± 0.03 0.74 ± 0.32 0.74 ± 0.19 0.75 ± 0.28 0.86 ± 0.39
C16:0 15.22 ± 2.00 15.06 ± 1.98 15.89 ± 1.86 18.94 ± 1.89 15.32 ± 2.11* 15.56 ± 1.54*
C:16:1 t 5.23 ± 1.18 5.16 ± 0.98 3.83 ± 1.18 5.73 ± 1.18 5.63 ± 0.26 5.83 ± 0.98
C16:1 2.86 ± 0.98 1.22 ± 0.81 0.97 ± 0.81 2.65 ± 0.90 2.65 ± 0.60 3.45 ± 1.86
C17:0 1.19 ± 0.23 1.52 ± 0.31 1.99 ± 0.23 1.45 ± 0.32 1.58 ± 0.26 2.49 ± 0.23
C18:0 21.82 ± 3.72 20.15 ± 3.56 19.36 ± 3.92 22.76 ± 1.72 18.73 ± 2.25* 18.36 ± 3.72*
C18:1 14.50 ± 1.06 12.69 ± 1.04* 12.50 ± 1.06* 13.40 ± 1.86 9.04 ± 2.02* 10.95 ± 2.06*
C:18:1 n-7 6.24 ± 0.98 5.06 ± 0.86 5.24 ± 0.95 5.31 ± 0.99 5.78 ± 0.67 5.44 ± 1.80
C18:2 t n-6 2.35 ± 0.46 2.26 ± 0.46 2.35 ± 0.84 3.86 ± 0.86 3.35 ± 0.76 3.35 ± 0.46
C18:2 n-6 2.97 ± 0.43 2.65 ± 0.34 2.40 ± 0.43 2.28 ± 0.58 2.59 ± 0.37 2.40 ± 0.73
C18:3 n-3 0.27 ± 0.17 0.37 ± 0.25 1.26 ± 0.87 0.17 ± 0.04 0.65 ± 0.25 0.67 ± 0.27
C20:0 0.31 ± 0.32 0.56 ± 0.12 0.66 ± 0.32 0.12 ± 0.02 0.18 ± 0.04 0.65 ± 0.32
C20:1 0.37 ± 0.03 0.38 ± 0.04 0.15 ± 0.03 0.24 ± 0.01 0.22 ± 0.02 0.87 ± 0.43
C20:2 1.79 ± 0.31 1.49 ± 0.28 1.15 ± 0.35 1.12 ± 0.05 1.36 ± 0.04 1.15 ± 0.41
C21:0 0.61 ± 0.26 0.51 ± 0.08 0.51 ± 0.26 1.06 ± 0.02 1.52 ± 0.21 1.17 ± 0.06
C20:3 n-6 1.14 ± 0.26 0.97 ± 0.17 1.02 ± 0.21 0.85 ± 0.18 0.93 ± 0.20 0.54 ± 0.06
C20:4 n-6 8.56 ± 1.15 6.67 ± 1.05* 5.59 ± 1.25* 7.67 ± 1.15 5.04 ± 0.19* 4.89 ± 0.25*
C20:3 n-3 0.65 ± 0.15 1.22 ± 0.39 0.90 ± 0.21 0.84 ± 0.19 0.70 ± 0.16 1.44 ± 0.59
C20:5 n-3 0.94 ± 0.25 5.52 ± 1.13* 0.91 ± 0.13 0.72 ± 0.13 5.52 ± 1.23* 0.91 ± 0.13
C23:0 1.14 ± 0.36 0.77 ± 0.56 0.99 ± 0.24 0.32 ± 0.15 0.29 ± 0.12 0.54 ± 0.36
C24:0 0.91 ± 0.13 0.73 ± 0.13 0.84 ± 0.25 0.58 ± 0.15 0.42 ± 0.14 0.99 ± 0.43
C22:5 n-3 3.18 ± 0.88 5.99 ± 1.23* 3.60 ± 0.48 3.05 ± 0.98 10.22 ± 2.08* 3.45 ± 0.96
C22:6 n-3 3.45 ± 0.96 2.97 ± 0.99 13.54 ± 2.89* 3.90 ± 0.56 4.24 ± 0.36 10.65 ± 1.23*
C24:1 1.91 ± 0.12 1.70 ± 0.19 1.54 ± 0.23 0.41 ± 0.11 0.28 ± 0.13 0.51 ± 0.23
n-3/n-6 PUFA 0.56 ± 0.08 1.35 ± 0.14* 1.85 ± 0.19* 0.59 ± 0.09 1.71 ± 0.18* 1.35 ± 0.15*
  1. All data are the mean ± S. D. for three separate experiments. PUFA: polyunsaturated fatty acids. *:p <0.05 as compared to the corresponding control; *:p <0.05 compared to the corresponding EPA treatment.